ADCs are no longer a niche modality. To date, there are over a dozen approved ADCs on the market, and more than 500 programs are in clinical development, driving the global market past $11 billion in 2023 and toward a projected compound annual growth... Read more
As the world recalibrates its life sciences infrastructure post-pandemic, Australia is stepping up as a regional powerhouse in biomanufacturing—especially in the realm of viral vectors and cell and gene therapy. At the heart of this transformat... Read more
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a significant leadership transition with the appointment of Jean-Charles Wirth and Danny Bar-Zohar to its Executive Board. Jean-Charles Wirth will assum... Read more
Enter Generative AI: A Paradigm Shift Today, generative AI is changing this equation. Unlike traditional AI that analyzes existing data, generative AI can create entirely new molecules—compounds designed from the ground up to meet specific the... Read more
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept ... Read more
Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast and flexible NGS data... Read more
Upstream phase of LUMEVOQ® manufacturing process successfully transferred Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and dose-ranging study in France Partnership expected... Read more
CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDA... Read more
© 2025 Biopharma Boardroom. All Rights Reserved.
